Perceptive Advisors LLC acquired a new stake in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the 4th quarter, HoldingsChannel reports. The firm acquired 1,000,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,880,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Two Sigma Investments LP acquired a new position in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $3,190,000. Two Sigma Advisers LP acquired a new position in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $314,000. BVF Inc. IL acquired a new position in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $4,632,000. Deutsche Bank AG raised its holdings in shares of Achillion Pharmaceuticals by 54.1% during the fourth quarter. Deutsche Bank AG now owns 2,566,018 shares of the biopharmaceutical company’s stock valued at $7,388,000 after purchasing an additional 900,859 shares during the period. Finally, Rock Springs Capital Management LP raised its holdings in shares of Achillion Pharmaceuticals by 5.6% during the fourth quarter. Rock Springs Capital Management LP now owns 2,250,000 shares of the biopharmaceutical company’s stock valued at $6,480,000 after purchasing an additional 118,600 shares during the period. Hedge funds and other institutional investors own 82.04% of the company’s stock.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $4.21 on Tuesday. Achillion Pharmaceuticals, Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $5.66. The firm has a market cap of $583.29, a PE ratio of -6.79 and a beta of 1.04.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same period in the prior year, the business posted ($0.03) EPS. equities research analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Monday, November 13th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. Leerink Swann reiterated a “buy” rating and set a $5.00 price objective on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Finally, B. Riley assumed coverage on shares of Achillion Pharmaceuticals in a report on Thursday, February 8th. They set a “neutral” rating and a $3.50 price objective on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.89.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/13/1000000-shares-in-achillion-pharmaceuticals-inc-achn-acquired-by-perceptive-advisors-llc.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.